Evaluation of coupled convective–diffusive transport of drugs administered by intravitreal injection and controlled release implant

Park, Ju‐Young; Bungay, Peter M.; Lutz, Robert J.; Augsburger, James J.; Millard, Ronald W.; Roy, Abhijit Sinha; Banerjee, Rupak K.

doi:10.1016/j.jconrel.2005.03.010

Cited by 97 publications

(92 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The average velocity at the retinal surface calculated from the model was 2.9×010 −7 cm/s, consistent with earlier analysis (17,34,35,40,41). The total aqueous outflow through the vitreous was 0.069 μl/min, which is 2.8% of the total aqueous humor produced.…”

Section: Pressure and Aqueous Permeation Velocitysupporting

confidence: 87%

Computer Modeling of Drug Delivery to the Posterior Eye: Effect of Active Transport and Loss to Choroidal Blood Flow

Balachandran

Barocas

2008

Pharm Res

View full text Add to dashboard Cite

show abstract

Section: Pressure and Aqueous Permeation Velocitysupporting

confidence: 87%

Computer Modeling of Drug Delivery to the Posterior Eye: Effect of Active Transport and Loss to Choroidal Blood Flow

Balachandran

Barocas

2008

Pharm Res

View full text Add to dashboard Cite

show abstract

“…After the vitreous humor is withdrawn, the aqueous humor, driven by intraocular pressure, will supplement the vacant space [63], which will slightly accelerate the convection of intraocular fluid and the elimination of drugs. Nevertheless, convection has a relatively minor influence for small molecule drugs and high diffusivity drugs [64].…”

Section: Discussionmentioning

confidence: 99%

Sustained intravitreal delivery of dexamethasone using an injectable and biodegradable thermogel

et al. 2015

View full text Add to dashboard Cite

“…Due to its high blood perfusion, the choroid is usually regarded as a sink in which the drug concentration is assumed to be zero when modeling drug transport in ocular tissues [76,77] . Systemic drug levels can be measured by acquiring blood samples, and tilisolol has been shown to be rapidly absorbed into the bloodstream after periocular injection [78] .…”

Section: Choroidal Clearancementioning

confidence: 99%

Transport Barriers in Transscleral Drug Delivery for Retinal Diseases

et al. 2007

Self Cite

View full text Add to dashboard Cite

Transscleral delivery has emerged as an attractive method for treating retinal disorders because it offers localized delivery of drugs as a less invasive method compared to intravitreal administration. Numerous novel transscleral drug delivery systems ranging from microparticles to implants have been reported. However, transscleral delivery is currently not as clinically effective as intravitreal delivery in the treatment of retinal diseases. Transscleral drug delivery systems require drugs to permeate through several layers of ocular tissue (sclera, Bruch’s membrane-choroid, retinal pigment epithelium) to reach the neuroretina. As a result, a steep drug concentration gradient from the sclera to the retina is established, and very low concentrations of drug are detected in the retina. This steep gradient is created by the barriers to transport that hinder drug molecules from successfully reaching the retina. A review of the literature reveals 3 types of barriers hindering transscleral drug delivery: static, dynamic and metabolic. While static barriers have been examined in detail, the literature on dynamic and metabolic barriers is lacking. These barriers must be investigated further to gain a more complete understanding of the transport barriers involved in transscleral drug delivery.

show abstract

Evaluation of coupled convective–diffusive transport of drugs administered by intravitreal injection and controlled release implant

Cited by 97 publications

References 17 publications

Computer Modeling of Drug Delivery to the Posterior Eye: Effect of Active Transport and Loss to Choroidal Blood Flow

Computer Modeling of Drug Delivery to the Posterior Eye: Effect of Active Transport and Loss to Choroidal Blood Flow

Sustained intravitreal delivery of dexamethasone using an injectable and biodegradable thermogel

Transport Barriers in Transscleral Drug Delivery for Retinal Diseases

Contact Info

Product

Resources

About